Reducing Post-Operative Opioid Prescribing in Southeastern North Carolina
Building an Implementation Science Network to Reduce Post-Operative Opioid Prescribing in Southeastern North Carolina
The goal of this stepped-wedge cluster randomized trial is to evaluate whether an opioid stewardship intervention improves post-operative opioid prescribing practices. Participants will include surgeon champions and identified change team members (e.g., pharmacists, hospitalists, nurses, advanced practice providers, anesthesiologists, etc.) and patient representatives at designated hospital sites in North Carolina.
The main questions it aims to answer are:
I. Does the intervention reduce postoperative opioid prescribing behavior at the surgeon and hospital level? II. Is the intervention acceptable, feasible, and effective for implementation among participating hospitals?
Researchers will compare opioid prescribing and implementation outcomes across sites before and after implementation using a stepped-wedge cluster randomized design, in which sites are randomly assigned to different intervention start times.
Participants will attend educational sessions delivered, introduce the Standard Opioid Prescribing (SOPS) Toolkit into their clinical practice, review benchmarked, deidentified opioid prescribing performance reports that use administrative claims data (secondary data source, data not collected or shared between hospitals), and complete surveys assessing intervention acceptability, feasibility, and effectiveness. Preliminary effectiveness will be assessed through reduction of opioid prescriptions using administrative claims data.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
A stepped-wedge cluster randomized trial will be conducted across participating hospital sites in Southeastern North Carolina. Sites will transition sequentially from the control condition to the intervention condition based on randomization, until all clusters have completed the opioid stewardship intervention over a 10-week period.
During the control phase, opioid prescribing will continue according to existing practices. During the intervention phase, sites will implement a multi-component site-specific opioid stewardship intervention. The intervention includes dissemination of the Standard Opioid Prescribing (SOPS) Toolkit, quality improvement (QI) educational sessions, and benchmarked opioid prescribing performance reports generated from administrative claims data. These reports provide deidentified surgeon- and site-level prescribing summaries so that sites are able to see their current opioid prescribing levels.
The primary outcomes are the acceptability, feasibility, and effectiveness of the intervention assessed during and after implementation as determined from semi-structured interviews and surveys. Secondary outcomes include additional provider and patient opioid prescribing outcomes related to post-operative opioid fills by patients. This information will be obtained from administrative claims data. No patient information will be collected and no patient will be enrolled int eh study. These measures evaluate whether tailoring the opioid stewardship intervention to each hospital improves routine clinical practice and provider opioid prescribing.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Jessica Schumacher, PhD
- Número de telefone: (919) 966-4320
- E-mail: Jessica_Schumacher@med.unc.edu
Estude backup de contato
- Nome: Meaghan Hazelet
- E-mail: meaghan.hazelet@med.unc.edu
Locais de estudo
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27514
- University of North Carolina at Chapel Hill
-
Contato:
- Jessica Schumacher, PhD
- Número de telefone: 919-966-4320
- E-mail: Jessica_Schumacher@med.unc.edu
-
Investigador principal:
- Jessica Schumacher, PhD
-
Wilmington, North Carolina, Estados Unidos, 28401
- Novant Health New Hanover Regional Medical Center
-
Contato:
- William Hope, MD
- E-mail: william.hope@novanthealth.org
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
Surgeon champions and identified change team members must be currently practicing at one of the sites participating in this study.
Patient representatives must be:
Proficient in the English language Prescribed opioids following a qualifying general surgery procedure (inpatient or outpatient laparoscopic appendectomy, inguinal/femoral hernia repair, umbilical hernia, bariatric/weight loss surgery, mastectomy, laparoscopic cholecystectomy, laparoscopic colectomy, lipoma/soft tissue tumor excision, and anal/rectal procedures).
No patients will be enrolled for this trial. However, claims data will be used to assess the claims based outcome measure (opioid prescribing).
Inclusion criteria for the claims analysis includes:
Patients greater than or equal to 18 at the time of a qualifying general surgery procedure either inpatient or outpatient (laparoscopic appendectomy; umbilical/ventral/inguinal/femoral hernia repair; bariatric/weight loss surgery; mastectomy; laparoscopic cholecystectomy; laparoscopic colectomy; lipoma/soft tissue tumor excision; anal/rectal procedures) based on procedure codes Patients must have continuous insurance coverage (including prescription drug coverage), 6 months before to 60 days post discharge to assess comorbidities and prescription drug fills.
Exclusion Criteria:
Patients with an opioid fill 6 months before the procedure. Patients who undergo a significant operation during the stay associated with their index procedure that would require additional pain management.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Pesquisa de serviços de saúde
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Outro: Usual Care (Control Period)
During the control phase of the stepped wedge cluster randomized trial, participating hospitals continue opioid prescribing according to existing local practices.
Clinicians do not receive any components of the opioid stewardship intervention during this period.
Each hospital contributes data to this arm prior to crossing over to the intervention phase based on randomized timing.
|
Existing opioid prescribing practices and guidelines at each participating hospital site, with no additional educational, benchmarking, or quality improvement activities.
|
|
Experimental: Opioid Stewardship Intervention (Intervention Period)
During the intervention phase, hospitals implement a multi component opioid stewardship intervention after crossing over from the control condition according to randomized start time.
Clinician participants at each site engage in the intervention for approximately 10 weeks.
All hospitals eventually receive the intervention as part of the stepped wedge design.
|
A multi component intervention consisting of dissemination of the Standard Opioid Prescribing (SOPS) Toolkit, quality improvement educational sessions for clinicians, and benchmarked opioid prescribing performance reports generated from administrative claims data.
Reports provide deidentified surgeon and site level summaries of opioid prescribing patterns.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Acceptability of the Intervention Assessed by Semi-Structured Interviews (Change Team Members)
Prazo: From enrollment through 6 months after completion of the 10-week intervention period
|
Acceptability will be assessed qualitatively using themes derived from semi-structured interviews conducted with change team members.
Interviews will explore perceptions of the intervention and its fit within the hospital context.
Themes identified after the 10-week implementation period will be compared with themes identified prior to implementation.
|
From enrollment through 6 months after completion of the 10-week intervention period
|
|
Proportion of training and learning sessions attended (Feasibility Measure 1)
Prazo: From enrollment through 6 months after completion of the 10-week intervention period
|
Proportion of training and learning sessions attended by change team members
|
From enrollment through 6 months after completion of the 10-week intervention period
|
|
percentage of change team member providers that completed pre- and post- assessments (Feasibility Measure 2)
Prazo: From enrollment through 6 months after completion of the 10-week intervention period
|
percentage of change team member providers that completed pre- and post- assessments
|
From enrollment through 6 months after completion of the 10-week intervention period
|
|
change team's ability to start the trial as randomized (Feasibility Measure 3)
Prazo: From enrollment through 6 months after completion of the 10-week intervention period
|
change team's ability to start the trial as randomized (yes/no)
|
From enrollment through 6 months after completion of the 10-week intervention period
|
|
proportion of intervention components implemented (Feasibility Measure 4)
Prazo: From enrollment through 6 months after completion of the 10-week intervention period
|
proportion of intervention components implemented using themes gathered from semi-structured interviews (intervention fidelity)
|
From enrollment through 6 months after completion of the 10-week intervention period
|
|
Change in Organizational Readiness to Change (ORIC) Measure (Effectiveness Measure 1- survey)
Prazo: From enrollment through 6 months after completion of the 10-week intervention period)
|
Change in ORIC score from pre- to post intervention.
Change team members will complete the survey before the intervention start phase and after intervention completion.
|
From enrollment through 6 months after completion of the 10-week intervention period)
|
|
Audit and feedback effectiveness as assessed by learning sessions and semi structured interviews (Effectiveness Measure 2)
Prazo: Intervention Period
|
Audit and feedback effectiveness is defined as the extent change team members feel ownership and agreement, can make sense of the information provided, are motivated by the social influence that reviewing their performance shows (e.g., comparing their performance to other hospitals), and accept accountability for the proposed changes.
|
Intervention Period
|
|
Change in Milligram equivalents (MME) of the first post-operative fill pre- and post-intervention using administrative claims data (Effectiveness Measure 3).
Prazo: Comparing pre (6 months before enrollment) and 6 month period starting at the end of the 10-week intervention period.
|
Change in Milligram equivalents (MME) of the first opioid prescription filled (outpatient) by patients -3 days before admission for their qualifying procedure through 7 days post-discharge during the pre- and post-intervention time periods.
|
Comparing pre (6 months before enrollment) and 6 month period starting at the end of the 10-week intervention period.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Second opioid fill within 60-days of discharge (yes/no) using administative claims data
Prazo: From enrollment through 6 months after completion of the 10-week intervention period
|
For patients with one or more post-operative opioids filled, the proportion that filled a second prescription within 60 days of discharge from the qualifying procedure
|
From enrollment through 6 months after completion of the 10-week intervention period
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Jessica Schumacher, PhD, University of North Carolina, Chapel Hill
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- 25-1636
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .